Fractyl Health (GUTS) Cash from Investing Activities (2023 - 2025)
Fractyl Health's (GUTS) quarterly Cash from Investing Activities came in at -$3000.0 in Q4 2025, up 98.71% YoY from -$1509.7 in Q4 2024, and up 62.5% on a QoQ basis from -$8000.0 in Q3 2025.
Fractyl Health (GUTS) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Fractyl Health (GUTS) has 3 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 98.71% year-over-year to -$3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$557000.0 (up 68.44% YoY) and the FY2025 annual result came in at -$557000.0, up 68.44% from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q4 2025, from -$8000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$3000.0 in Q4 2025 to a low of -$1.1 million in Q1 2024.
- A 3-year average of -$223416.7 and a median of -$142000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 5195.0% — and 2025, when it jumped 98.71%.
- Tracing GUTS's Cash from Investing Activities over 3 years: stood at -$136000.0 in 2023, then plunged by 71.32% to -$233000.0 in 2024, then jumped by 98.71% to -$3000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$3000.0 (Q4 2025), -$8000.0 (Q3 2025), and -$98000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -448,000.00 |
| Mar 31, 2025 | -448,000.00 |
| Dec 31, 2024 | -233,000.00 |
| Dec 31, 2024 | -233,000.00 |
| Sep 30, 2024 | -213,000.00 |
| Sep 30, 2024 | -213,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Mar 31, 2024 | -1.06 Mn |
| Mar 31, 2024 | -1.06 Mn |
| Dec 31, 2023 | -136,000.00 |
| Dec 31, 2023 | -136,000.00 |
| Sep 30, 2023 | -148,000.00 |
| Sep 30, 2023 | -148,000.00 |